Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Organon & Co(OGN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for OGN
10/26/2026: OGN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Organon & Co is a healthcare company focused on women's health, biosimilars, and a portfolio of established pharmaceutical brands. Its primary strengths lie in its specialized focus on women's reproductive health and the steady cash flows generated by its legacy products. The company's main growth opportunity is leveraging its growing biosimilar portfolio and expanding in women's health markets. However, investors must consider the risks related to the company's significant debt, reliance on mature products, and intense pharmaceutical competition. Organon is generally suited for value or dividend-focused investors, and participants should monitor its debt reduction progress and the success of new biosimilar product launches.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential in women's health but is tempered by the maturity of established brands. |
| Momentum investor | Weak fit | The stock has not consistently shown the strong upward trend required for momentum strategies. |
| Value investor | Strong fit | The company is often traded at low multiples relative to its cash flow generation. |
| Dividend investor | Strong fit | The dividend yield is attractive, supported by the stable cash flow of legacy products. |
| Low-risk investor | Mixed fit | While established products provide stability, the debt levels add a layer of risk for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock price can be sensitive to quarterly earnings reports and changes in debt management sentiment. |
| Valuation risk | Low | The stock is generally priced at a valuation that reflects its steady but slow-growth nature. |
| Competition risk (Pharmaceutical) | High | The company faces intense competition from both branded pharmaceutical companies and generic producers. |
| Business quality | Medium | The company has a solid, though aging, product portfolio that requires constant management. |
| Dividend income | Medium | The dividend is reliable, but the company must balance payouts with its significant debt obligations. |
| Execution risk | Medium | Successful integration of acquisitions and management of product lifecycles are critical to performance. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 34.29% | Avg. Invested days 60 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/26/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.61B USD | Price to earnings Ratio 17.63 | 1Y Target Price 11.25 |
Price to earnings Ratio 17.63 | 1Y Target Price 11.25 | ||
Volume (30-day avg) 2.2M shares | Beta 1.54 | 52 Weeks Range 5.67 - 13.83 | Updated Date 10/25/2026 |
52 Weeks Range 5.67 - 13.83 | Updated Date 10/25/2026 | ||
Dividends yield (FY) 0.58% | Basic EPS (TTM) 0.78 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Women's Health | Contraception and fertility products like Nexplanon and Follistim. | This is the core innovation area and long-term growth engine for the company. |
| Established Brands | A wide portfolio of legacy drugs in respiratory, cardiovascular, and pain management. | These products provide the steady cash flow that funds dividends and R&D. |
| Biosimilars | Biologic therapies including oncology and inflammatory medicine equivalents. | This segment provides an opportunity to capture market share from high-cost branded biologicals. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 17.63 | Forward PE 5.09 | Enterprise Value 11.01B | Price to Sales(TTM) 0.59 |
Enterprise Value 11.01B | Price to Sales(TTM) 0.59 | ||
Enterprise Value to Revenue 1.8 | Enterprise Value to EBITDA 8.39 | Shares Outstanding 262.61M | Shares Floating 243.05M |
Shares Outstanding 262.61M | Shares Floating 243.05M | ||
Percent Insiders 0.46 | Percent Institutions 84.61 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.